Health Care · Pharmaceutical Preparations

ARVN ARVINAS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 165575993 filings
Russell 2000

ARVN at a glance

ARVINAS, INC. (ARVN, SEC CIK 1655759) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ARVINAS, INC. (ARVN) reported revenue of $262.6 million (down 0.3% from FY2024) and a net loss of $80.8 million. Diluted EPS was -$1.14.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding ARVINAS, INC. (ARVN) shares worth $254.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Loomis David K on November 9, 2026 of 232 shares at $6.36 per share.
  • In the last 90 days, ARVN insiders reported 0 open-market purchases ($0) and 1 open-market sale ($1K) on Form 4, a net sale of $1K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$262.6M
−0.3% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$1K
13F holders
30 funds
$254.4M · +0 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New risk triggered by AI deployment: AI and machine learning use in PROTAC discovery introduces data, cybersecurity, intellectual-property and operational exposure
  • Most materially updated risk: Rigel now controls VEPPANU pricing, reimbursement, sublicensing and ex-U.S. regulatory decisions
  • Regulatory risk: EU AI Act became fully effective in August 2026, increasing high-risk AI compliance obligations
  • Operational risk: VEPPANU commercialization depends entirely on Rigel’s funding and execution
  • Financial risk: No committed external funding source before substantial product-sale revenue generation

Management Discussion & Analysis

  • Q3 revenue $0.5M, down $41.4M YoY from $41.9M, reflecting nonrecurring collaboration and milestone revenue
  • Q3 net loss $53.9M vs $35.1M YoY, with R&D expense $46.9M vs $64.7M
  • Best R&D growth: ARV-393 expense $5.8M vs $2.6M; worst: vepdegestrant expense $0 vs $14.2M
  • Cash, equivalents, restricted cash and marketable securities $558.9M vs $685.4M at December 31, 2025; operating cash use $127.9M
  • Funding runway into second half of 2028; ARV-102 PSP trial on clinical hold pending FDA review

AI summary of the ARVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Corporate update accompanying quarterly results

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation dated November 3, 2026
  • Exhibit 99.2 contains investor materials for review

Item EX-99.2: Item EX-99.2

  • Investor presentation highlights ARV-393 Phase 1 enrollment in relapsed/refractory NHL, with initial monotherapy data targeted for 4Q 2026
  • Updated ARV-393 monotherapy and glofitamab-combination data targeted for mid-2027, creating near-term clinical catalysts

Item EX-99.1: Item EX-99.1

  • Q3 revenue $0.5M versus $41.9M, reflecting the loss of prior Pfizer and Novartis milestone revenue
  • Cash, restricted cash and marketable securities $558.9M, funding planned operations into 2H 2028
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Second-quarter 2026 financial results for period ended June 30, 2026
  • Corporate update announced alongside quarterly results

Item EX-99.1: Item EX-99.1

  • Q2 revenue $249.7M vs $22.4M, driven by $126.4M deferred-revenue recognition, $62.5M Rigel license revenue, and $50.0M approval milestone
  • VEPPANU became the first FDA-approved PROTAC, while Rigel obtained exclusive global rights, shifting commercialization execution away from Arvinas
Filed Jun 25, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Leslie V. Norwalk and Randy Teel elected as Class II directors through 2029
  • Norwalk received 33,199,341 votes, with 10,607,126 withheld

AI summaries of ARVN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ARVN

Don't miss the next ARVN filing

  • Alerts as it files. A push when ARVN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ARVN, by share count.
  • Ask anything. An AI agent that reads every ARVN filing and answers with sources.

ARVN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Loomis David KSellNov 9, 2026$6.36
Smaldone Alsup LaurieAJun 24, 2026-
Saik AndrewSellJun 24, 2026$8.16
Norwalk Leslie VAJun 24, 2026-
Cunningham EverettAJun 24, 2026-
Smaldone Alsup LaurieAJun 24, 2026-
Kennedy Edward Moore Jr.AJun 24, 2026-
Cunningham EverettAJun 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$263.4M$262.6M
Operating Income-$401.5M-$250.2M-$118.5M
Net Income-$367.3M-$198.9M-$80.8M
Op. Margin--95.0%-45.1%
Net Margin--75.5%-30.8%
Balance Sheet
Total Assets-$1.1B$717.9M
Equity-$561.7M$433.9M
ROE--35.4%-18.6%
Per Share
EPS$-6.62$-2.77$-1.14
Cash Flow
Operating CF--$259.3M-$273.8M
CapEx$2.9M$1.8M$1.9M

Source: XBRL data in ARVINAS, INC. (ARVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ARVN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ARVN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$254.4M
Q2 202630$275.8M
Q1 202628$321.9M
Q4 202525$363.6M
Q3 202526$282.2M
Q2 202527$280.0M
Q1 202522$169.1M
Q4 202419$377.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 207 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ARVN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 9, 2026--
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
8-KJun 25, 2026Analysis-
4Jun 24, 2026--
8-KJun 22, 2026Analysis-
4Jun 18, 2026--
8-KJun 16, 2026Analysis-
8-KJun 2, 2026Analysis
4May 22, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
8-KMay 12, 2026Analysis
8-KMay 12, 2026Analysis

Related Health Care companies

All Health Care →

ARVN SEC filings: frequently asked questions

Are ARVN insiders buying or selling?

In the last 90 days, ARVINAS, INC. (ARVN) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $1,475 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ARVN stock?

As of September 30, 2026, the largest ARVINAS, INC. (ARVN) holders among the 13F filers tracked by SignalX were BlackRock ($63.8 million), Vanguard Portfolio Management LLC ($32.3 million), Pfizer Inc ($26.2 million), D.E. Shaw & Co ($24.8 million), Vanguard Capital Management LLC ($20.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ARVN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ARVINAS, INC. (ARVN) reported revenue of $262.6 million (down 0.3% from FY2024) and a net loss of $80.8 million. Diluted EPS was -$1.14. The figures come from the XBRL data in the 10-K.

What did ARVN report in its latest 8-K?

ARVINAS, INC. (ARVN) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest ARVN SEC filings?

ARVINAS, INC. (ARVN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 9, 2026.

What is ARVN's SEC CIK number?

ARVINAS, INC. (ARVN)'s SEC Central Index Key (CIK) is 1655759. EDGAR lists every ARVN filing under that number.

Ask anything about ARVN

The research agent reads ARVN's filings, financials, insider trades and 13F holders, then answers with sources.